• Linshom Management

  Led · Grant · May 2024

  Linshom Medical develops a wearable, FDA-cleared sensor that delivers an operating-room quality respiratory profile at the bedside or home for continuous, predictive respiratory monitoring (CPRM). Its device reports Respiratory Rate (RR), relative Tidal Volume (rTV) and Seconds Since Last Breath (SSLB) continuously and in real time. The company says the CPRM aims to reduce data delay, false alarms, and complicated implementation associated with existing monitoring options, enabling earlier detection of respiratory decline. Linshom has initiated a clinical study, “Advanced Prediction of Respiratory Depression Episodes with Linshom Continuous Predictive Respiratory Monitoring (CPRM),” to evaluate early detection in the Post Anesthesia Care Unit. That study is being led by Dr. Samuel M. Galvagno of the University of Maryland School of Medicine. Linshom is currently raising a Series A Preferred round of investment. Linshom Medical delivers an Operating Room–quality respiratory profile to the patient bedside and home via a patented, FDA-cleared sensor and system for continuous, predictive respiratory monitoring (CPRM). The system provides continuous, real-time Respiratory Rate (RR), relative Tidal Volume (rTV) and Seconds Since Last Breath (SSLB). The company’s stated mission is to eliminate morbidity, mortality and cost due to unrecognized respiratory compromise in healthcare. The NIH NHLBI FastTrack award will fund a clinical study to validate Linshom’s early-detection capability for respiratory decline. The award also supports further miniaturization of the technology toward a nasal cannula form factor and a wearable sensor for home monitoring. Linshom is currently raising a Series A Preferred round of investment. Linshom Medical is a Maryland-based startup developing a respiratory monitoring system. Its Linshom Respiratory Sensor and Monitor is described as the first predictive, continuous respiratory monitoring system able to practically reach the patient bedside. The system is intended to bridge the monitoring gap between critical care and general care floors so clinicians can respond more quickly to severe respiratory-related events. The article notes severe respiratory events can cause brain damage within three minutes after breathing ceases, and that half of adverse events occur on general care floors with 75% of those being respiratory in nature. Linshom closed a $1.5 million Series A with investment from the Maryland Momentum Fund and current investors. CEO Richard Hughen said the Momentum Fund’s commitment has triggered a spike of interest from other investors.

• Polaris Genomics

  Led · Grant · Jul 2022

  Polaris Genomics, founded in 2017 and based in Gaithersburg, Md., builds genomic-based diagnostics to make mental-health conditions diagnosable by clinical tests rather than subjective questionnaires. Its products include TruGen-1, a 1003-gene panel for neuropsychiatric research, the PTS-ID blood screen for PTSD risk, and a pipeline diagnostic called PTS-Dx. The company emerged from an Illumina accelerator and was founded by Charles Cathlin and Tshaka Cunningham. Polaris frames genomics as a way to connect mental illness to biological underpinnings to reduce stigma and improve early identification. Financially, the company has raised $3.4 million to date and relies heavily on grant and government funding in addition to private investment. Notable non-dilutive support includes a $200,000 George Shultz Innovation Fund grant, a $1.25 million AFWERX Phase II SBIR award, a $100,000 Maryland Industrial Partnerships matching grant, and $250,000 from the VA MissionDaybreak challenge. Polaris Genomics develops genomic diagnostics and research tools focused on neuropsychiatric conditions, notably the PTS-ID genomic blood test for identifying PTSD, measuring disease severity, and detecting treatment response. Its product suite includes the PTS-ID test, the TruGen-1 1003-gene research panel, the TruNorth data-integration platform, and laboratory services through Endeavor Lab. The company is woman-, Black-, and veteran-led and works with academic partners such as the University of Maryland Baltimore. Polaris has received targeted public research funding from the Maryland Industrial Partnership Program (MIPS) to advance validation and commercialization. Current work focuses on validating biomarkers in larger and more diverse cohorts and testing the biomarkers’ ability to detect changes with treatment. Leadership states the near-term aim is to move rapidly toward product commercialization to serve veterans, first responders, frontline workers, and trauma-impacted communities.

• CyDeploy

  Led · Grant · Feb 2021

  CyDeploy provides a platform that automates creation of digital twins and delivers on‑demand sandbox environments for security and functional testing. Its core product lets CIOs evaluate the functional impact of changes without touching production systems, reducing risk and deployment anxiety. The company positions that capability for both security testing and broader change-validation workflows. CyDeploy was founded by Tina Williams‑Koroma (CEO) with technical co‑founder and President of Engineering David Steadman. The company is based in Baltimore and is an active participant in the Techstars ’23 Equitech Accelerator. Financially, CyDeploy recently closed an oversubscribed $1.1M pre‑seed funding round to support product development and participation in the accelerator program. CyDeploy uses artificial intelligence and machine learning to create cloud-based replicas of a company’s systems so teams can test cybersecurity updates without risking production environments. The platform is intended to validate updates and configuration changes for IT systems and Internet of Things devices, including consumer devices and medical equipment. Founder Tina Williams-Koroma, an alum of UMBC and founder of cybersecurity risk firm TCecure, launched CyDeploy in 2019 after hearing clients ask what would break if they made security changes. In 2020 the company developed a paper prototype and in 2021 plans to begin piloting the product with enterprises and management service providers. CyDeploy is working with UMBC professor Anupam Joshi to develop the tool and is soliciting pilot participants via direct contact. The company estimates a five-year need of about $1.5 million to continue development and commercialization; it recently received a $90,000 grant to build a functioning prototype at UMBC.

No current team members are available.